Spirogen’s Antibody-Drug Conjugate (ADC) technology delivers extremely potent anticancer agents to cancer cells by attaching them to antibodies.
We have developed highly potent warheads based on our proprietary PBDs. These PBD warheads are joined to antibodies by linkers which are stable in the bloodstream but release the PBD warhead once it is safely inside the targeted cancer cells.
Evident in our data, ADCs developed using PBDs demonstrate superior in vivo anti-tumor activity.
PBD ADC at equivalent dose produces significantly better anti-tumor activity than auristatin and maytansinoid-based HER2 ADCs
Durable growth delay with C2-Anilino PBD-ADC at 1 mg/kg
No effect with gemtuzumab ozogamicin (Mylotarg) at 1 mg/kg
Good activity with C2-Anilino PBD-ADC at 0.3 mg/kg
Complete responses to PBD-ADC SC16LD6.5 (Rovalpituzumab teserine) in a SCLC PDX model.